drug · small molecule
patient view →osimertinib mesylate
Marketedupdated 2mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $6.6B
community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and 1 investigational indication.
indications
investigational
NSCLC
targets
Epidermal growth factor receptor
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that